Perspective Therapeutics has dosed the first patients in new cohorts of two ongoing Phase 1/2a clinical trials testing their radiopharmaceuticals [212 Pb]VMT-α-NET for neuroendocrine tumors and [212 Pb]PSV359 for solid tumors. The new dosing regimen for VMT-α-NET aims to optimize response and tolerability by front-loading doses, while PSV359 targets tumors expressing FAP-α with up to four doses every eight weeks. These studies are important steps in developing targeted alpha radiation therapies that may improve cancer treatment efficacy and safety. Further data and trial updates are expected throughout 2026.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
DMG Blockchain Solutions announced two strategic investments: one in MeetAmi Innovations, a Canadian fintech offering digital asset wealth management platforms, and another in Atomic47 Labs, an AI company focused on secure, sovereign AI infrastructur...
Gnosis (GNO) surged 13% in 24 hours, closing in on overtaking BONK by market capitalization to reach the 100th largest token spot. GNO's market cap stands at $303.88 million versus BONK's $330.07 million, requiring a price rise to about $125.48 for t...
Broadridge's Tokenization Pulse Survey shows 84% of firms view tokenization as strategically important, with 68% expecting it to reshape markets within 3-5 years. Most firms plan to integrate tokenization into existing infrastructure rather than buil...
Standard Chartered has partnered with Broadcom to modernize its global banking infrastructure by adopting a secure, resilient private cloud using VMware Cloud Foundation. This upgrade supports critical banking services across 54 markets with enhanced...
